FDA cited G.N.R. Group's frozen coconut juice safety plan for pasteurization too weak to control Clostridium botulinum.
What happened
FDA inspected the Bangkok food manufacturing facility from January 22 to January 23, 2024, and issued a Form FDA-483, a list of inspection observations, citing serious deviations from the juice Hazard Analysis and Critical Control Point (HACCP) rules. FDA found that the firm's HACCP plan for Frozen Coconut Juice set pasteurization limits that were not sufficient to consistently produce a 5-log reduction, about a 100,000-fold reduction, in non-proteolytic Clostridium botulinum, and that the firm did not provide documentation proving the process works.
What FDA found
The company's HACCP plan for Frozen Coconut Juice set pasteurization limits that did not reliably achieve the required 5-log reduction in non-proteolytic Clostridium botulinum, the hazard FDA said must be controlled in this low-acid juice.
21 CFR 120.24(a)FDA said the firm did not provide documentation showing its pasteurization process would repeatedly and reliably produce the required microbial reduction.
21 CFR 120.24(a)Because the required HACCP system was not implemented, FDA said the juice products are adulterated, meaning prepared under conditions that may make them injurious to health.
21 CFR 120.9; FD&C Act Section 402(a)(4)
What FDA wants
Within 15 working days, FDA asks the company to write with specific corrective steps, supporting documents, and data showing the thermal process repeatedly achieves the required 5-log reduction; FDA also recommends engaging a process authority. If corrective actions cannot be completed in that time, the company must state why and give a completion date.
Who should pay attention
- U.S. importers and brands that buy frozen coconut juice from Thailand
- juice processors relying on pasteurization limits for low-acid products
- distributors of frozen fruit and vegetable products
This is a summary. Read the original letter on fda.gov.